Colossal Biosciences vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Colossal Biosciences is the world's first de-extinction company; $555M raised, $10.2B decacorn valuation; targeting woolly mammoth embryos by 2026, dire wolves already created Mar 2025.
About
Colossal Biosciences is the world's first commercial de-extinction and genomic engineering company, applying CRISPR gene editing and synthetic biology to resurrect extinct species and restore ecological balance. Founded in 2021 by tech entrepreneur Ben Lamm and Harvard geneticist George Church, Colossal is simultaneously pursuing the de-extinction of the woolly mammoth, the Tasmanian thylacine, the dodo bird, the dire wolf, and the bluebuck antelope — building the scientific and technological infrastructure to produce living specimens of each. The company's Dallas, Texas headquarters anchors a multi-disciplinary team spanning computational biology, developmental biology, reproductive science, and conservation ecology.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
AI Visibility Head-to-Head
Key Details
Also Compare
Colossal Biosciences vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.